Copyright: ©Author(s) 2027. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Jan 7, 2027; 33(1): 122785
Published online Jan 7, 2027. doi: 10.3748/wjg.122785
Published online Jan 7, 2027. doi: 10.3748/wjg.122785
Efficacy and safety of surufatinib and anti-PD-L1 therapy in combination with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
Rong-Ce Zhao, Xin-Hao Xiong, Liang-He Lu, Jie Mei, Wei Wei, Rong-Ping Guo, Department of Liver Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Jing Zhou, Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Co-first authors: Rong-Ce Zhao and Xin-Hao Xiong.
Co-corresponding authors: Wei Wei and Rong-Ping Guo.
Author contributions: Zhao RC and Xiong XH contributed equally as co-first authors; Zhao RC, Xiong XH, Zhou J, Mei J, and Lu LH contributed to data curation and writing - original draft; Zhao RC, Xiong XH, Zhou J, Mei J, Lu LH, Wei W, and Guo RP contributed to methodology; Zhao RC, Xiong XH, Zhou J, Wei W, and Guo RP completed formal analysis; Zhao RC, Xiong XH, and Zhou J completed conceptualization, software, and visualization; Wei W and Guo RP completed funding acquisition, supervision, and writing - review and editing as co-corresponding authors. All authors approved the final version to publish.
AI contribution statement: The authors take full responsibility and accountability for all content of this manuscript, including any portions for which AI tools were used as assistive technologies. All AI-assisted outputs were carefully reviewed, validated, and approved by the authors. AI tools were not used to generate original scientific data, perform independent scientific analyses, or draw scientific conclusions.
Supported by National Natural Science Foundation of China, No. 82303879 and No. 82303875.
Institutional review board statement: This study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center, No. B2024-665-Y01.
Informed consent statement: The Ethics Committee has exempted the informed consent of the patients.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data used during this study are available from the corresponding author upon reasonable request.
Corresponding author: Rong-Ping Guo, Professor, Department of Liver Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou 510060, Guangdong Province, China. guorp@sysucc.org.cn
Received: April 29, 2026
Revised: June 19, 2026
Accepted: July 29, 2026
Published online: January 7, 2027
Processing time: 194 Days and 19.5 Hours
Revised: June 19, 2026
Accepted: July 29, 2026
Published online: January 7, 2027
Processing time: 194 Days and 19.5 Hours
Core Tip
Core Tip: Combining surufatinib and anti-programmed death-ligand 1 therapy with hepatic arterial infusion chemotherapy yields promising antitumor activity and survival benefits for unresectable intrahepatic cholangiocarcinoma. This innovative regimen demonstrates a highly favorable safety profile, characterized by a low incidence of grade 3 or 4 adverse events. Notably, patients who respond to this combination therapy achieve significantly better prognostic outcomes compared to non-responders. These findings highlight a potent, well-tolerated therapeutic strategy that could substantially improve clinical management for unresectable intrahepatic cholangiocarcinoma.